Sarcoidosis drug study halted after just 3 patients
NCT ID NCT02134717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug maraviroc could reduce inflammation in the lungs of people with active sarcoidosis. Participants took the drug for 6 weeks and had two lung exams (bronchoscopy) to measure immune cells before and after treatment. Only 3 people enrolled, and the study was stopped early, so no clear conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dorothy P. and Richard P. Simmons center for Interstitial lung Disease at the University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States